These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 34709394)

  • 21. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
    Fletcher NL; Kempe K; Thurecht KJ
    Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review.
    Bai X; Smith ZL; Wang Y; Butterworth S; Tirella A
    Micromachines (Basel); 2022 Sep; 13(10):. PubMed ID: 36295976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment.
    El Moukhtari SH; Rodríguez-Nogales C; Blanco-Prieto MJ
    Adv Drug Deliv Rev; 2021 Jun; 173():238-251. PubMed ID: 33774117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanomedicine: novel approaches in human and veterinary therapeutics.
    Irache JM; Esparza I; Gamazo C; Agüeros M; Espuelas S
    Vet Parasitol; 2011 Aug; 180(1-2):47-71. PubMed ID: 21680101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functionalized Graphene Oxide for Chemotherapeutic Drug Delivery and Cancer Treatment: A Promising Material in Nanomedicine.
    Sharma H; Mondal S
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
    Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
    Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-based active targeting strategies for cancer theranostics.
    Bandyopadhyay A; Das T; Nandy S; Sahib S; Preetam S; Gopalakrishnan AV; Dey A
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3417-3441. PubMed ID: 37466702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surface engineered multifunctional nano-systems for localised drug delivery against thyroid cancer: A review of current practices.
    Zhang Y; Tang N; Zhou H; Zhu Y
    Biomed Pharmacother; 2024 Jul; 176():116840. PubMed ID: 38820975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical applications of nanomedicines in lung cancer treatment.
    Norouzi M; Hardy P
    Acta Biomater; 2021 Feb; 121():134-142. PubMed ID: 33301981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
    Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
    Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Redox Potential and ROS-Mediated Nanomedicines for Improving Cancer Therapy.
    Glass SB; Gonzalez-Fajardo L; Beringhs AO; Lu X
    Antioxid Redox Signal; 2019 Feb; 30(5):747-761. PubMed ID: 28990403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced nanomedicines for the regulation of cancer metabolism.
    Yang J; Zhao Y; Zhou Y; Wei X; Wang H; Si N; Yang J; Zhao Q; Bian B; Zhao H
    Biomaterials; 2022 Jul; 286():121565. PubMed ID: 35576808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Actively targeted nanocarriers for drug delivery to cancer cells.
    Biffi S; Voltan R; Bortot B; Zauli G; Secchiero P
    Expert Opin Drug Deliv; 2019 May; 16(5):481-496. PubMed ID: 30955393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.